PTC Therapeutics (PTCT) SVP Utter exercises options and sells 19,686 shares under 10b5-1 plan

Rhea-AI Filing Summary

PTC Therapeutics SVP and Chief Accounting Officer Christine Marie Utter reported an exercise-and-sell stock transaction. She exercised options to acquire 19,686 shares of common stock at $25.69 per share and sold 19,686 shares in the open market at $75.56 per share on the same date. After these transactions, she directly holds 70,199 shares of common stock and 15,314 stock options as shown in the derivative table. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026.

Insights

Equity compensation and insider-trading analyst

Routine option exercise-and-sell under a Rule 10b5-1 plan with sizable remaining holdings.

Christine Marie Utter, SVP and Chief Accounting Officer of PTC Therapeutics, exercised stock options for 19,686 shares at $25.69 and sold 19,686 shares at $75.56 in an open-market transaction. This is a classic exercise-and-sell pattern.

The option was granted in February 2024 and vests over four years, indicating these shares are part of a longer-term compensation program. Following the trades, she still directly holds 70,199 common shares and 15,314 options, so her equity exposure remains meaningful.

The sale was executed pursuant to a written Rule 10b5-1 plan adopted on March 17, 2026, suggesting the timing was pre-planned rather than reactive to short-term news. Future company filings may provide additional context as more tranches vest and similar transactions occur.

Insider Trade Summary 10b5-1

Net Seller: 19,686 shares ($1,487,474)

Net Sell 3 txns

Insider Utter Christine Marie

Role SVP, CHIEF ACCOUNTING OFFICER

Sold 19,686 shs ($1.49M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	19,686	$0.00	--
Exercise	Common Stock	19,686	$25.69	$506K
Sale	Common Stock	19,686	$75.56	$1.49M

Holdings After Transaction: Stock Option (Right to Buy) — 15,314 shares (Direct, null); Common Stock — 89,885 shares (Direct, null)

Footnotes (1)

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2026. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.

Key Figures

Shares sold: 19,686 shares Sale price: $75.56/share Exercise price: $25.69/share +5 more

8 metrics

Shares sold 19,686 shares Open-market sale of common stock on June 17, 2026

Sale price $75.56/share Price for 19,686 common shares sold

Exercise price $25.69/share Stock options exercised for 19,686 underlying shares

Shares held after sale 70,199 shares Direct common stock holdings following transactions

Options remaining 15,314 options Stock options outstanding after partial exercise

Rule 10b5-1 plan adoption date March 17, 2026 Date written trading plan was adopted

Option grant date February 15, 2024 Grant date for the reported stock option

Option expiration February 14, 2034 Expiration date for the stock option

Key Terms

Rule 10b5-1 plan, Stock Option (Right to Buy), open-market sale, derivative exercise/conversion, +2 more

6 terms

Rule 10b5-1 plan regulatory

"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" with underlying security title Common Stock"

open-market sale financial

"transaction_action: "open-market sale" with transaction code S for Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" with transaction code M"

vesting financial

"and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: "2034-02-14T00:00:00.000Z" for the stock option"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 05:20 PM Accepted by SEC EDGAR 06/22/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Utter Christine Marie

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF ACCOUNTING OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		M(1)		19,686	A	$25.69	89,885	D
Common Stock	06/17/2026		S(1)		19,686	D	$75.56	70,199	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$25.69	06/17/2026		M(1)			19,686	(2)	02/14/2034	Common Stock	19,686	$0	15,314	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2026.

2. This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.

	/s/ Avraham S. Adler, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did PTC Therapeutics (PTCT) executive Christine Utter do in this Form 4?

Christine Utter exercised stock options for 19,686 PTC Therapeutics shares at $25.69 and sold 19,686 shares at $75.56. The transactions reflect a routine exercise-and-sell pattern tied to equity compensation rather than a pure open-market purchase or sale.

How many PTC Therapeutics shares does Christine Utter hold after this Form 4?

After the reported transactions, Christine Utter directly holds 70,199 shares of PTC Therapeutics common stock. She also has 15,314 stock options remaining from the reported grant, providing additional potential equity exposure if those options are exercised in the future.

At what prices did Christine Utter transact PTC Therapeutics (PTCT) shares?

Christine Utter exercised stock options at an exercise price of $25.69 per share and sold 19,686 shares at $75.56 per share. These figures show the spread between her option strike price and the market sale price on the transaction date.

Was Christine Utter’s sale of PTCT shares under a Rule 10b5-1 trading plan?

Yes. The filing states the transaction was effected under a written Rule 10b5-1 trading plan adopted on March 17, 2026. Such plans pre-schedule trades, indicating the timing of this sale was planned rather than a discretionary reaction to recent events.

What stock option grant is involved in Christine Utter’s PTCT Form 4?

The Form 4 references a stock option granted on February 15, 2024. It vests over four years, with 25% vesting on February 15, 2025, and an additional 6.25% of the original shares vesting at the end of each three-month period starting May 15, 2025.

Does this Form 4 show remaining stock options for Christine Utter at PTC Therapeutics?

Yes. After exercising 19,686 options, the derivative table shows 15,314 stock options remaining. These options relate to the same grant and continue to vest over time according to the four-year vesting schedule described in the filing’s footnote.